A Phase 3 Study of Elranatamab + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants with Newly Diagnosed Multiple Myeloma

Full Title

MAGNETISMM-6: An Open-Label, 2-Arm, Multicenter, Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dexamethasone In Transplant-Ineligible Participants With Newly Diagnosed Multiple Myeloma (Advarra)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Alexander Lesokhin’s office at 646-608-3717.